Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Metergoline→

Metergoline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
17692-51-2
Molecular formula
C25H29N3O2
Molecular weight
403.5 g/mol
Drug class
Ergoline alkaloiddopamine agonist and serotonin receptor antagonist
Mechanism of action
An ergot-derived ergoline with dopamine agonist activity and antagonistic activity at multiple serotonin receptor subtypes, including 5-HT2 receptors. Its pharmacology also includes inhibitory effects on prolactin secretion.
Indications / reported uses
  • Historically used in selected countries for migraine disorders and prolactin-related conditions; it is not a standard contemporary first-line treatment and current authorisation varies by jurisdiction.

Sources: https://www.ncbi.nlm.nih.gov/mesh/68008711 · https://meshb.nlm.nih.gov/record/ui?dcmsLinks=true&ui=D008711 · https://pubchem.ncbi.nlm.nih.gov/compound/28693 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Metergoline Environmental Risk Assessment (ERA) (the Metergoline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.